Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypogammaglobulinemia, Acquired Clear all
Terminated No phase listed Observational

Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)

NCT01883921
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Immunoglobulin Therapy
Other
Lead sponsor
BriovaRx Infusion Services
Industry
Eligibility
7 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 3, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT02579967
View directory record Official record
Conditions
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune Lymphoproliferative, Lymphoproliferative Disorders
Interventions
Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L, GVHD Prophylaxis, Allo BMT
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2036
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Respiratory Microbiota and Immune Response in CVID

NCT06173128
View directory record Official record
Conditions
CVID
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

NCT00115778
View directory record Official record
Conditions
Hypogammaglobulinemia, Lung Transplantation
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

A Clinical Study of Intravenous Immunoglobulin

NCT00468273
View directory record Official record
Conditions
Immunologic Deficiency Syndromes
Interventions
Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
Drug
Lead sponsor
FFF Enterprises
Industry
Eligibility
3 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 3, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improving the Diagnosis of Common Variable Immune Deficiency

NCT03335605
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Bronchiectasis

NCT00943514
View directory record Official record
Conditions
Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT03663933
View directory record Official record
Conditions
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases, Common Variable Immunodeficiency
Interventions
e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning, GVHD Prophylaxis, Allogeneic HSC, Bisulfan, Prednisone, Cyclophosphamide, MMF, Mesna, Tacrolimus, Pentostatin, PFTs, DEXA, Bone Marrow Aspirate & Biopsy, EKG, 2D ECHO
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Leniolisib for Immune Dysregulation in CVID

NCT06897358
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID)
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Bethesda, Maryland • Burlington, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT03513328
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02435173
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
CDZ173, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 3, 2026, 2:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease

NCT05193552
View directory record Official record
Conditions
Common Variable Immunodeficiency
Interventions
Hizentra
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

NCT01884311
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinaemia, Hyperimmunoglobulin M Syndrome
Interventions
Subgam
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Chandler, Arizona • Irvine, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

NCT02199496
View directory record Official record
Conditions
Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
Interventions
Stelara (ustekinumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 3, 2026, 2:08 PM EDT